Sex differences in cerebral venous sinus thrombosis after adenoviral vaccination against COVID-19

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
SAGE PUBLICATIONS LTD
Autores
SCUTELNIC, Adrian
MUNCKHOF, Anita van de
KRZYWICKA, Katarzyna
KAMMEN, Mayte Sanchez van
LINDGREN, Erik
CORDONNIER, Charlotte
KLEINIG, Timothy J.
FIELD, Thalia S.
POLI, Sven
LEMMENS, Robin
Citação
EUROPEAN STROKE JOURNAL, v.8, n.4, p.1001-1010, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Cerebral venous sinus thrombosis associated with vaccine-induced immune thrombotic thrombocytopenia (CVST-VITT) is a severe disease with high mortality. There are few data on sex differences in CVST-VITT. The aim of our study was to investigate the differences in presentation, treatment, clinical course, complications, and outcome of CVST-VITT between women and men. Patients and methods: We used data from an ongoing international registry on CVST-VITT. VITT was diagnosed according to the Pavord criteria. We compared the characteristics of CVST-VITT in women and men. Results: Of 133 patients with possible, probable, or definite CVST-VITT, 102 (77%) were women. Women were slightly younger [median age 42 (IQR 28-54) vs 45 (28-56)], presented more often with coma (26% vs 10%) and had a lower platelet count at presentation [median (IQR) 50x10(9)/L (28-79) vs 68 (30-125)] than men. The nadir platelet count was lower in women [median (IQR) 34 (19-62) vs 53 (20-92)]. More women received endovascular treatment than men (15% vs 6%). Rates of treatment with intravenous immunoglobulins were similar (63% vs 66%), as were new venous thromboembolic events (14% vs 14%) and major bleeding complications (30% vs 20%). Rates of good functional outcome (modified Rankin Scale 0-2, 42% vs 45%) and in-hospital death (39% vs 41%) did not differ. Discussion and conclusions: Three quarters of CVST-VITT patients in this study were women. Women were more severely affected at presentation, but clinical course and outcome did not differ between women and men. VITT-specific treatments were overall similar, but more women received endovascular treatment.
Palavras-chave
VITT, CVST, sex differences
URI
https://observatorio.fm.usp.br/handle/OPI/59185
Referências
  1. [Anonymous], 2021, JOINT CDC FDA STATEM
  2. [Anonymous], 2021, VACCINE UPDATE
  3. de Sousa DA, 2020, STROKE, V51, P1174, DOI 10.1161/STROKEAHA.119.028532
  4. Elberry MH, 2022, J THROMB THROMBOLYS, V53, P798, DOI 10.1007/s11239-021-02626-w
  5. Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840
  6. Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
  7. Krzywicka K, 2022, NEUROLOGY, V98, pE759, DOI 10.1212/WNL.0000000000013148
  8. Matar RH, 2022, BLOOD COAGUL FIBRIN, V33, P90, DOI 10.1097/MBC.0000000000001113
  9. Pai MAK, 2022, SEMIN HEMATOL, V59, P72, DOI 10.1053/j.seminhematol.2022.02.002
  10. Pavord S, 2021, NEW ENGL J MED, V385, P1680, DOI 10.1056/NEJMoa2109908
  11. Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x
  12. Schulz JB, 2021, ANN NEUROL, V90, P627, DOI 10.1002/ana.26172
  13. Scutelnic A, 2022, ANN NEUROL, V92, P562, DOI 10.1002/ana.26431
  14. Sharifian-Dorche M, 2021, J NEUROL SCI, V428, DOI 10.1016/j.jns.2021.117607
  15. Silvis SM, 2017, NAT REV NEUROL, V13, P555, DOI 10.1038/nrneurol.2017.104
  16. Thiele T, 2022, LANCET REG HEALTH-EU, V12, DOI 10.1016/j.lanepe.2021.100270
  17. van den Bergh WM, 2005, NEUROLOGY, V65, P192, DOI 10.1212/01.wnl.0000179677.84785.63
  18. van Kammen MS, 2021, JAMA NEUROL, V78, P1314, DOI 10.1001/jamaneurol.2021.3619
  19. Whitacre CC, 2001, NAT IMMUNOL, V2, P777, DOI 10.1038/ni0901-777

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - COVID-19